Literature DB >> 12951578

p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases.

Sanjay Kumar1, Jeffrey Boehm, John C Lee.   

Abstract

The p38 MAP kinases are a family of serine/threonine protein kinases that play important roles in cellular responses to external stress signals. Since their identification about 10 years ago, much has been learned of the activation and regulation of the p38 MAP kinase pathways. Inhibitors of two members of the p38 family have been shown to have anti-inflammatory effects in preclinical disease models, primarily through the inhibition of the expression of inflammatory mediators. Several promising compounds have also progressed to clinical trials. In this review, we provide an overview of the role of p38 MAP kinases in stress-activated pathways and the progress towards clinical development of p38 MAP kinase inhibitors in the treatment of inflammatory diseases.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12951578     DOI: 10.1038/nrd1177

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


  321 in total

Review 1.  Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities.

Authors:  Brian J Nickoloff; Frank O Nestle
Journal:  J Clin Invest       Date:  2004-06       Impact factor: 14.808

2.  Development of an online p38α mitogen-activated protein kinase binding assay and integration of LC-HR-MS.

Authors:  David Falck; Jon S B de Vlieger; Wilfried M A Niessen; Jeroen Kool; Maarten Honing; Martin Giera; Hubertus Irth
Journal:  Anal Bioanal Chem       Date:  2010-08-22       Impact factor: 4.142

3.  Differential pharmacological behaviour of p38 inhibitors in regulating the LPS-induced TNF-α production in human and rat whole blood in vitro.

Authors:  Mercè Pont-Giralt; Núria Godessart; Cristina Balagué
Journal:  Inflammation       Date:  2011-04       Impact factor: 4.092

4.  Decreased collagen-induced arthritis severity and adaptive immunity in MKK-6-deficient mice.

Authors:  Deepa Hammaker; Katharyn Topolewski; Meghan Edgar; Toshio Yoshizawa; Akihisa Fukushima; David L Boyle; Esther Cory Burak; Robert L Sah; Gary S Firestein
Journal:  Arthritis Rheum       Date:  2012-03

5.  Slack sodium-activated potassium channel membrane expression requires p38 mitogen-activated protein kinase phosphorylation.

Authors:  Sushmitha Gururaj; John Fleites; Arin Bhattacharjee
Journal:  Neuropharmacology       Date:  2015-12-22       Impact factor: 5.250

6.  Elevated brain monoamine oxidase activity in SIV- and HIV-associated neurological disease.

Authors:  Kelly A Meulendyke; Ceereena Ubaida-Mohien; Julia L Drewes; Zhaohao Liao; Lucio Gama; Kenneth W Witwer; David R Graham; M Christine Zink
Journal:  J Infect Dis       Date:  2014-03-31       Impact factor: 5.226

7.  Helicobacter pylori-induced interleukin-12 p40 expression.

Authors:  Eriko Takeshima; Koh Tomimori; Hiromitsu Teruya; Chie Ishikawa; Masachika Senba; Daniele D'Ambrosio; Fukunori Kinjo; Hitomi Mimuro; Chihiro Sasakawa; Toshiya Hirayama; Jiro Fujita; Naoki Mori
Journal:  Infect Immun       Date:  2009-01-29       Impact factor: 3.441

Review 8.  Mechanistic systems biology of inflammatory gene expression in airway smooth muscle as tool for asthma drug development.

Authors:  Chi-Ming Hai
Journal:  Curr Drug Discov Technol       Date:  2008-12

9.  Pyridinyl imidazole inhibitors of p38 MAP kinase impair viral entry and reduce cytokine induction by Zaire ebolavirus in human dendritic cells.

Authors:  Joshua C Johnson; Osvaldo Martinez; Anna N Honko; Lisa E Hensley; Gene G Olinger; Christopher F Basler
Journal:  Antiviral Res       Date:  2014-05-09       Impact factor: 5.970

10.  Autophagy-dependent PELI3 degradation inhibits proinflammatory IL1B expression.

Authors:  Annika Klara Giegerich; Laura Kuchler; Lisa Katharina Sha; Tilo Knape; Heinrich Heide; Ilka Wittig; Christian Behrends; Bernhard Brüne; Andreas von Knethen
Journal:  Autophagy       Date:  2014-10-30       Impact factor: 16.016

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.